Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HTI), sold 25,000 shares at $8.05 ($199K) on 2007-03-14, disclosed to the SEC on 2007-03-16.
Scheduled sale ($199k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.81 | 400 | $3K | 1.6% |
| 2 | $7.83 | 400 | $3K | 1.6% |
| 3 | $7.84 | 200 | $2K | 0.8% |
| 4 | $7.85 | 3,000 | $24K | 11.8% |
| 5 | $7.86 | 1,200 | $9K | 4.7% |
| 6 | $7.87 | 1,200 |
| $9K |
| 4.7% |
| 7 | $7.88 | 500 | $4K | 2.0% |
| 8 | $7.89 | 300 | $2K | 1.2% |
| 9 | $7.90 | 100 | $790 | 0.4% |
| 10 | $7.94 | 100 | $794 | 0.4% |
| 11 | $7.95 | 3,500 | $28K | 14.0% |
| 12 | $7.96 | 400 | $3K | 1.6% |
| 13 | $8.00 | 7,100 | $57K | 28.5% |
| 14 | $8.01 | 1,600 | $13K | 6.4% |
| 15 | $8.02 | 2,200 | $18K | 8.9% |
| 16 | $8.05 | 2,800 | $23K | 11.3% |
| Total | $7.96 avg | 25,000 | $199K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |